New York, June 2 - Alphatec Holdings, Inc. priced its $83.7 million initial public offering of common stock at $9.00 per share, below the target price range of $11.00 to $12.00.
Deutsche Bank Securities and First Albany Capital were joint bookrunners with RBC Capital Markets as co-manager.
The deal has a greenshoe for 1.395 million shares.
Alphatec will use $35.7 million of the $71.4 million net proceeds to meet redemption obligations and to pay dividends to existing shareholders. A further $26.3 million will be used to expand the company's sales and marketing, to support its research and development, to fund the clearance or approval and subsequent commercialization of near-term product candidates, and to acquire complementary businesses, products or technologies, or to obtain rights to complementary technologies.
An additional $9.4 million will be used to repay debt, including repaying $6.8 million outstanding on the company's revolving credit facility with Bank of the West and $2.6 million to repay a loan to chairman, president and chief executive officer Shunshiro "Roy" Yoshimi.
Following the IPO, Alphatec has 34.76 million shares outstanding.
Alphatec is a Carlsbad, Calif., medical device company concentrating on products for the surgical treatment of spine disorders.
Issuer: | Alphatec Holdings, Inc.
|
Issue: | Initial public offering
|
Gross proceeds: | $83.7 million
|
Net proceeds: | $71.4 million
|
Shares: | 9.3 million
|
Greenshoe: | 1.395 million shares
|
Price: | $9.00
|
Pricing date: | June 1, after close
|
Bookrunners: | Deutsche Bank Securities, First Albany Capital
|
Guidance: | $11.00 to $12.00
|
Stock symbol: | Nasdaq: ATEC
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.